NEWSROOM
Discover all the actions carried out by Jeito and all the partnerships that we set up day after day for the well-being of patients and medical progress.
In the headlines
Jeito Capital leads EUR 132 million oversubscribed Series B financing in Azafaros to advance Phase 3 clinical programs of innovative therapies in rare inherited neuro-metabolic disorders
Proceeds will support two Phase 3 pivotal programs with nizubaglustat, lead asset in Niemann-Pick disease Type C disease and GM1/GM2 gangliosidoses, three forms of rare lysosomal storage disorders, as well as expanding Azafaros pipeline to other indications The...
Download our White Paper
We are pleased to share with you our White Paper, which offers a deep dive into the evolving biopharma landscape and highlights the key trends shaping its future.
Find all our press releases
Sanofi selects Jeito Capital as its first investment into a private French-based fund
Paris, France, 13 November 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent investor...
Jeito Capital becomes major investor in SparingVision as part of €44.5 Million financing
Jeito Capital has selected SparingVision as its first French investment following the fund I...
Rafaèle Tordjman, Founder and CEO of Jeito, is awarded Chevalier of the Légion d’Honneur
Paris, France, 30 September 2020 – Jeito Capital (“Jeito”), a rapidly emerging independent...
Jeito Capital co-leads $110 Million Series A Financing in Neogene Therapeutics
Neogene becomes Jeito Capital’s first investment following the fund I launch in January 2020 Round...
Rafaèle Tordjman launches JEITO CAPITAL, a new private equity company dedicated to biotech-biopharmaceuticals
Paris, January 13, 2020 - Rafaèle Tordjman launches JEITO CAPITAL, a new French and independent...
Face to face
Meet Jeito
12-15
January
All day long
JPM Healthcare Conference 2026
Jeito will be present at the 44th JPM Healthcare Conference 2026, renowned as the largest and most influential healthcare investment symposium, attracting global industry leaders, Biotech companies, and members of the investment community, in San Francisco.